Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction sintilimab plus chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in locally advanced esophageal squamous cell carcinoma
ChiCTR2400091065Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2400091065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091065.